Article
Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib.
Scientific reports - 20 Jan 2020
Ishii Hidenobu, Azuma Koichi, Sakai Kazuko, Naito Yoshiko, Matsuo Norikazu, Tokito Takaaki, Yamada Kazuhiko, Hoshino Tomoaki, Nishio Kazuto
Abstract excerpt
Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) were developed to target the EGFR T790M resistance mutation in non-small cell lung cancer (NSCLC) patients resistant to first- or second-generation EGFR-TKIs. To investigate the efficacy of afatinib treatment for EGFR T790M-positive NSCLC patients showing resistance to osimertinib and alterations in somatic mutations and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.